Based on TCGA database bioinformatics analysis combined with immunohistochemical verification, we confirmed that CD34/CD276 could be used as a molecular marker for CRC prognosis and promote CRC immune escape by relying on the down-regulation mechanism of m6A modification. Here, CD34 is linked to colorectal carcinoma.